A Phase 3 Study of KHK4827 in Patients With Systemic Sclerosis

Summary

To evaluate the efficacy and safety of KHK4827 in patients with systemic sclerosis who have moderate to severe skin thickening

Timeline

Start

2019-05-23

Primary completion

2020-10-16

Completion

2025-04-11

Outcome

Met primary endpoint

release “The primary endpoint of this study was the change from baseline in mRSS at Week 24. Significant decreases in mRSS were observed in brodalumab-treated arm” kyowakirin.com ↗

Drugs

Indications